

CRED Compiling Successful Clinical Trial Applications

10-11 March 2026, London

DAY 1: Compiling Successful Clinical Trial applications

Chairperson: Shaila Choi, Azafaros Switzerland AG

Time	Session/ Activity	Presenter
08:30	Registration and Coffee	
08:45	Welcome from TOPRA	TOPRA
09:00	Introduction to the next 2 days	Shaila Choi Azafaros Switzerland AG
09:10	Introduction to Clinical trials & Essential Documents <ul style="list-style-type: none"> • ICH/GCP • IB, Protocol, IMPD • Risk:Benefit • Comparators • RSI 	Stephen Thompson S Cubed
10:15	Tea and Coffee	
10:45	Overview of the EU-CTR <ul style="list-style-type: none"> • Initiation of clinical trials • Regulation 536/2014 • Portal and Database • Practical considerations • Experience 	Pierre-Frédéric Omnes TransPerfect
12:00	Lunch	
13:00	Maintenance considerations <ul style="list-style-type: none"> • Maintenance; Modifications, Temp Halts, Safety reporting, EoT activities, reporting obligations, archiving, TMF • Transparency & Disclosure Practical considerations	Pierre-Frédéric Omnes TransPerfect Stephen Thompson S Cubed
14:30	Tea and Coffee	
15:00	CTR Demo	Pierre-Frédéric Omnes TransPerfect
16:00	Agency's perspective on CTAs - EU <ul style="list-style-type: none"> • Hot Topics and Common Issues with CTAs 	Claudia Riedel BFARM
17:15	Close of meeting – Day 1	

DAY 2: Global considerations for Clinical Trial Applications
Chairperson: Stephen Thompson, S Cubed

Time	Session/ Activity	Presenter
09:00	Welcome and Introduction to the day	Stephen Thompson S Cubed
09:10	GCP inspections <ul style="list-style-type: none"> • Overview and types of GCP Inspections • How the RA professional needs to prepare for an Inspection • What to expect in the Inspection • TMF 	Bob Ibbotson Shionogi BV
10:00	Tea and Coffee break	
10:30	Global Regulatory Lead: Product development & Strategic considerations <ul style="list-style-type: none"> • Study design • Choice and provision of comparators, populations, SOC • Considerations for study conduct • Scientific advice • How regulatory interacts with clinical in clinical development • Open label extension studies, Named patient supply, Early access programs, Compassionate use 	Matthew Scullion J&J Innovative Medicines
12:00	Lunch	
13:00	RoW CTs: <ul style="list-style-type: none"> • FDA • SwissMedic • LATAM • APAC • UK 	Stephen Thompson S Cubed
14:30	Tea and coffee break	
15:00	Agency's perspective on CTAs - UK <ul style="list-style-type: none"> • Hot Topics and Common Issues with CTAs 	Kingyin Lee MHRA
16:15	Closing summary of the day	Stephen Thompson S Cubed
16:30	Close the meeting	